Hisun Pharmaceutical: Subsidiary HSK50042 Tablets gain new indication "Notice of Drug Clinical Trial Approval"

Huawei announced that its subsidiary Shanghai Huawei Shengnuo Pharmaceutical Technology Co., Ltd. recently received the "Notice of Approval for Drug Clinical Trials" issued by the National Medical Products Administration. According to the "Drug Administration Law of the People's Republic of China" and relevant regulations, after review, the HSK50042 tablets accepted in December 2025 meet the relevant requirements for drug registration, and it is approved to conduct clinical trials on this product. HSK50042 tablets are independently developed by the company, an oral, potent, highly selective small molecule inhibitor drug. This is another new indication approved for clinical trials in the field of respiratory diseases.